Immunocore announces key appointments to management and Board
16 févr. 2021 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore announces key appointments to management and Board Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp Dr. Roy S. Herbst appointed as a...
Immunocore Announces Pricing of Upsized Initial Public Offering
04 févr. 2021 22h07 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Pricing of Upsized Initial Public Offering OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc...
Immunocore announces closing of $75.0 Million Series C round
11 janv. 2021 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore announces closing of $75.0 Million Series C round Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma ...
Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020
03 déc. 2020 06h01 HE
|
Immunocore Limited
PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3...
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
27 août 2020 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
27 août 2020 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy
06 mai 2020 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy (OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md., 6 May 2020) Immunocore, a...
Immunocore Secures $130 Million Series B Financing
02 mars 2020 07h00 HE
|
Immunocore Limited
Immunocore Secures $130 Million Series B Financing Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic ...
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
19 nov. 2018 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech First-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple...
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
19 nov. 2018 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech First-in-human clinical trial of IMC-C103C scheduled to commence in 2019 in multiple...